These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 7137962)

  • 1. 3-O-methyldopa blocks dopa metabolism in rat corpus striatum.
    Reches A; Fahn S
    Ann Neurol; 1982 Sep; 12(3):267-71. PubMed ID: 7137962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catechol-O-methyltransferase and Parkinson's disease.
    Reches A; Fahn S
    Adv Neurol; 1984; 40():171-9. PubMed ID: 6695593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Favorable effect of catechol-O-methyltransferase inhibition by OR-462 in experimental models of Parkinson's disease.
    Lindén IB; Nissinen E; Etemadzadeh E; Kaakkola S; Männistö P; Pohto P
    J Pharmacol Exp Ther; 1988 Oct; 247(1):289-93. PubMed ID: 3171977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of carbidopa on plasma and muscle levels of L-dopa, dopamine, and their metabolites following L-dopa administration to rats.
    Rose S; Jenner P; Marsden CD
    Mov Disord; 1988; 3(2):117-25. PubMed ID: 3221899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
    Biggs CS; Starr MS
    Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3-O-Methyldopa inhibits astrocyte-mediated dopaminergic neuroprotective effects of L-DOPA.
    Asanuma M; Miyazaki I
    BMC Neurosci; 2016 Jul; 17(1):52. PubMed ID: 27456338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.
    Parada A; Loureiro AI; Vieira-Coelho MA; Hainzl D; Soares-da-Silva P
    Eur J Pharmacol; 2001 May; 420(1):27-32. PubMed ID: 11412836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catechol-O-methyltransferase inhibition by U-0521 increases striatal utilization of levodopa.
    Reches A; Jiang D; Fahn S
    Naunyn Schmiedebergs Arch Pharmacol; 1982 Jul; 320(1):34-7. PubMed ID: 7121609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats.
    Treseder SA; Rose S; Jenner P
    Eur J Neurosci; 2001 Jan; 13(1):162-70. PubMed ID: 11135014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of acute levodopa on brain catecholamines after selective MAO and COMT inhibition in male rats.
    Männistö PT; Tuomainen P; Toivonen M; Törnwall M; Kaakkola S
    J Neural Transm Park Dis Dement Sect; 1990; 2(1):31-43. PubMed ID: 2113389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
    Huang L; Deng M; Zhang S; Fang Y; Li L
    Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of L-dopa on striatal acetylcholine release: effects of 6-hydroxydopamine.
    Jackson D; Abercrombie ED; Zigmond MJ
    J Pharmacol Exp Ther; 1993 Nov; 267(2):912-8. PubMed ID: 8246167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
    Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T
    Exp Neurol; 2004 Jul; 188(1):65-73. PubMed ID: 15191803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of 3-O-methyl on L-dopa-facilitated synthesis and efflux of dopamine from rat striatal slices.
    Chang WY; Webster RA
    Br J Pharmacol; 1995 Nov; 116(6):2637-40. PubMed ID: 8590982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antiparkinsonian drug budipine stimulates the activity of aromatic L-amino acid decarboxylase and enhances L-DOPA-induced dopamine release in rat substantia nigra.
    Biggs CS; Fisher A; Starr MS
    Synapse; 1998 Nov; 30(3):309-17. PubMed ID: 9776134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism.
    Melamed E; Hefti F; Wurtman RJ
    Ann Neurol; 1980 Dec; 8(6):558-63. PubMed ID: 6260009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
    Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R
    Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
    St-Hilaire M; Landry E; Lévesque D; Rouillard C
    Neurobiol Dis; 2005 Nov; 20(2):450-60. PubMed ID: 15896973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of 3-O-methyldopa, L-3,4-dihydroxyphenylalanine metabolite, on locomotor activity and dopamine turnover in rats.
    Onzawa Y; Kimura Y; Uzuhashi K; Shirasuna M; Hirosawa T; Taogoshi T; Kihira K
    Biol Pharm Bull; 2012; 35(8):1244-8. PubMed ID: 22863920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.